UCB's mixed results and conservative guidance hit share price

23 February 2017

Belgian drugmaker UCB (Euronext Brussels: UCB) took a 3% hit to its share price as Thursday's treading neared its end after announcing a mixed set of annual financial results.

The Brussels-based company increased its total revenue by 8% to 4.18 billion euros ($4.42 billion) in 2016, the results showed, though this was well below the figure of 4.47 billion euros predicted by analysts polled by Reuters.

Investors will also note that net profit dropped from 2015’s 674 million euros by 20%, falling to 542 million euros in a decline partly caused by UCB’s 2015 sale of its Kremers Urban unit, which had provided windfall profit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK